Jacobs Levy Equity Management, Inc Cyclerion Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.56 - $2.99 $142,404 - $272,942	-91,285 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.73 - $4.13 $249,208 - $377,007	91,285 New	91,285 $280,000
Q2 2021 Aug 16, 2021	SELL	$2.18 - $4.29 $432,093 - $850,312	-198,208 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$2.69 - $5.12 $251,544 - $478,776	93,511 Added 89.32%	198,208 $553,000
Q4 2020 Feb 16, 2021	SELL	$2.25 - $7.12 $34,562 - $109,370	-15,361 Reduced 12.79%	104,697 $320,000
Q3 2020 Nov 16, 2020	SELL	$3.46 - $8.39 $104,948 - $254,485	-30,332 Reduced 20.17%	120,058 $730,000
Q2 2020 Aug 17, 2020	BUY	$2.37 - $7.14 $110,603 - $333,209	46,668 Added 44.99%	150,390 $889,000
Q1 2020 May 15, 2020	SELL	$2.46 - $5.84 $300,880 - $714,284	-122,309 Reduced 54.11%	103,722 $275,000
Q4 2019 Feb 14, 2020	BUY	$1.8 - $13.43 $272,719 - $2.03 Million	151,511 Added 203.32%	226,031 $615,000
Q3 2019 Nov 14, 2019	BUY	$8.12 - $14.54 $475,190 - $850,895	58,521 Added 365.78%	74,520 $903,000
Q2 2019 Aug 13, 2019	BUY	$9.6 - $22.85 $153,590 - $365,577	15,999 New	15,999 $183,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $153M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.